Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically ...

The second trial, CIRIFOUR, investigated nadunolimab combination therapy with pembrolizumab in 15 heavily pretreated patients ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will highlight new data from across its approved and investigational cancer therapies during the 2024 European Society ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 ...

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from two clinical trials of nadunolimab combination therapy ...

As you know, we opened three Phase 1 trials studying liver metastases, primary liver or bile duct cancer and locally ... for nelitolimod monotherapy, or nelitolimod combined with single-agent ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it will present the latest data of CD73 ...